Drug firm AstraZeneca Pharma India has inked a distribution agreement with Abbott Healthcare to distribute a diabetes medicine 'Dapagliflozin' in India. Dapagliflozin, an innovative Type 2 diabetes medicine, is a leading diabetes medicine of AstraZeneca Pharma.
AstraZeneca Pharma said, "Under the agreement, Abbott will promote and distribute Dapagliflozin under the brand name GLEDEPA. Abbott will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name GLEDEPA MET."
The drug company will continue to promote and distribute dapagliflozin under the brand name Forxiga and combination of dapagliflozin with metformin under the brand name Xigduo.
